NCT02475317View on ClinicalTrials.gov

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

December 1, 2015

Study Completion Date

December 1, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo

Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.

DRUG

Maralixibat

Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

DRUG

Volixibat

Participants will receive volixibat in 10 mg and 20 mg doses.

Trial Locations (1)

Unknown

New Orleans Center for Clinical Research, Knoxville

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY